Elekta AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EKTAF research report →
About the company
Elekta AB (publ) is a global medical technology enterprise providing advanced clinical tools for the treatment of cancer and neurological conditions. Their extensive product portfolio includes leading solutions for radiotherapy, such as Versa HD for brain metastases, the innovative Elekta Unity MR-Linac, Elekta Harmony linear accelerator, and systems like Elekta Infinity and Elekta Synergy for diverse radiotherapy needs, including advanced image guidance. They also offer comprehensive treatment management, quality assurance, and motion management technologies.
- CEO
- Jakob Just-Bomholt
- IPO
- 2010
- Employees
- 4,541
- HQ
- Stockholm, SE
Price Chart
- Market Cap
- $1.85B
- P/E
- -38.63
- P/S
- 1.15
- P/B
- 2.83
- EV/EBITDA
- 13.36
- Div Yield
- 4.59%
- Gross Margin
- 37.39%
- Op Margin
- 5.29%
- Net Margin
- -3.10%
- ROE
- -6.37%
- ROIC
- 5.87%
- Revenue
- $16.61B · -7.82%
- Net Income
- $-516,574,573 · -317.96%
- EPS
- $-1.38 · -322.58%
- Op Income
- $431.14M
- FCF YoY
- 120.51%
- 52W High
- $6.83
- 52W Low
- $4.48
- 50D MA
- $6.00
- 200D MA
- $5.85
- Beta
- 0.96
- Avg Volume
- 169
Get TickerSpark's AI analysis on EKTAF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our EKTAF coverage
Recent articles, reports, and earnings notes.
No research on EKTAF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EKTAF report →Similar companies
Peers in the same neighborhood.